JB/CALL/BASILEA PHARMA/60/0.05/21.06.24 Share Price

Warrant

BSZIJB

CH1242797095

Market Closed - Swiss Exchange 16:20:00 18/10/2023 BST
0.02 CHF -33.33% Intraday chart for JB/CALL/BASILEA PHARMA/60/0.05/21.06.24
3 months-71.43%
6 months-88.24%

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying BASILEA PHARMACEUTICA AG
Issuer Bank Julius Bär
BSZIJB
ISINCH1242797095
Date issued 22/02/2023
Strike 60 CHF
Maturity 21/06/2024 (14 Days)
Parity 20 : 1
Emission price 0.49 CHF
Emission volume N/A
Settlement both
Currency CHF

Technical Indicators

Highest since issue 0.46 CHF
Lowest since issue 0.02 CHF
Spread 0.01 CHF
Spread %50.00%

Company Profile

Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.
Sector
-
More about the company

Ratings for Basilea Pharmaceutica AG

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Basilea Pharmaceutica AG

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
42.2 CHF
Average target price
70.58 CHF
Spread / Average Target
+67.26%
Consensus
  1. Stock Market
  2. Warrants
  3. BSZIJB Warrant
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW